Baker Bros. Advisors LP Bei Gene, Ltd. Transaction History
Baker Bros. Advisors LP
- $9.34 Billion
- Q3 2024
A detailed history of Baker Bros. Advisors LP transactions in Bei Gene, Ltd. stock. As of the latest transaction made, Baker Bros. Advisors LP holds 10,568,897 shares of BGNE stock, worth $2.05 Billion. This represents 25.41% of its overall portfolio holdings.
Number of Shares
10,568,897
Previous 10,568,897
-0.0%
Holding current value
$2.05 Billion
Previous $1.51 Billion
57.36%
% of portfolio
25.41%
Previous 20.04%
Shares
8 transactions
Others Institutions Holding BGNE
# of Institutions
249Shares Held
45.3MCall Options Held
292KPut Options Held
119K-
Capital International Investors Los Angeles, CA6.43MShares$1.25 Billion0.29% of portfolio
-
Hhlr Advisors, Ltd. Grand Cayman, E95.18MShares$1.01 Billion26.65% of portfolio
-
Primecap Management CO Pasadena, CA4.97MShares$966 Million0.84% of portfolio
-
Baillie Gifford & CO3.71MShares$720 Million0.64% of portfolio
-
Price T Rowe Associates Inc Baltimore, MD2.7MShares$525 Million0.07% of portfolio
About BeiGene, Ltd.
- Ticker BGNE
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 103,700,000
- Market Cap $20.1B
- Description
- BeiGene, Ltd., a biotechnology company, focuses on discovering, developing, manufacturing, and commercializing various medicines worldwide. Its products include BRUKINSA to treat relapsed/refractory (R/R) mantle cell lymphoma; Tislelizumab to treat R/R classical Hodgkin's lymphoma; REVLIMID to treat multiple myeloma; VIDAZA to treat myelodysplas...